CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 6, 2025-- Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for patients with spinal muscular atrophy (SMA) and other severe and debilitating neuromuscular diseases, today reported financial results and updates for the second quarter ended June 30, 2025. “Our BLA is progressing under priority review towards our September 22 PDUFA date, and our team is working with urgency to prepare
Related Questions
Did Scholar Rock provide revised guidance or raise its 2025 sales outlook in this release?
How does apitegromab’s mechanism of action differentiate it from existing SMA competitors and what are the implications for market share?
What is the projected market size for apitegromab and its potential peak‑annual revenue?
How will the upcoming PDUFA decision on September 22 affect Scholar Rock’s valuation?
What is the stock’s price sensitivity to changes in FDA timelines or upcoming trial read‑outs?
How does the company’s cash runway compare to peers developing SMA therapies?
Are there any new clinical trial data or endpoint updates that could materially move the stock?
What upside and downside scenarios should be modeled for Q3 and Q4 earnings based on the BLA outcome and cash‑flow assumptions?
What were Scholar Rock’s Q2 2025 revenue, earnings, and cash balance versus analyst expectations and prior quarters?
What risks does the priority‑review BLA status pose for potential approval delays or label restrictions?
What are the expected R&D and SG&A expenditures for the remainder of 2025 and how will they impact margins?
Could potential partnership or licensing agreements for apitegromab generate additional non‑dilutive capital in the near term?